La Jolla Pharmaceutical is focused on the development and commercialization of therapies. GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA (eravacycline) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections. Co. owns various product candidates that are in preclinical development including: TP-6076, an IV formulation of a synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The LJPC stock yearly return is shown above.
The yearly return on the LJPC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LJPC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|